TEVA Teva Pharmaceutical Industries Ltd
$41.16
▲ 0.1%Updated Oct 16, 2:25 PM ET
Report Card
TEVA at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: Weak · 33/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Price — Past Year
▲ Up 106.5% in the year to Jul 6, 2026
Key Metrics
Market Cap
$32.95B
P/E
25.77x
Forward P/E (est.)
—
ROE
20.7%
Revenue Growth
4.4%
EPS Growth
—
Profit Margin
9.0%
FCF Yield
-10.5%
Debt / Equity
2.12x
ROIC
5.0%
Interest Coverage
2.35x
Current Ratio
0.88x
Dividend Yield
—
Implied Growth (rev. DCF)
5.3%
Rating Score
33/100
Business Overview
Teva Pharmaceutical Industries Ltd (TEVA) is a large-cap NYSE-listed company in the Pharmaceuticals industry, within the Health Care sector, with a market value around $32.95B.
In its latest reported year it generated about $17.26B in revenue and $1.41B in net profit.
Our model rates TEVA Weak (33/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Economic Moat
Evidence of durable competitive advantage in the filed financials (10 years of history).
Profit margins and economic moats, explainedSome durable-advantage evidence, but not across the board — dig into which ingredient is weak and whether it's cyclical or structural.
49.6% average over the last 3 years
±2.5 pts around 48.2% across 10 years
grew in 3 of the last 9 year-over-year periods
positive in 10 of 10 years
5.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical Analysis (Educational)
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what TEVA's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. TEVA trades near $41.16, above its 50-day average ($34.07) and 200-day average ($29.48). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 53 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. TEVA's is $1.16 (~2.8% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. In the month to Jul 6, 2026, TEVA found buyers near $30.80 (support) and sellers near $35.47 (resistance); its 52-week range then was $14.99–$37.35. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.3× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. The indicators were last computed on Jul 6, 2026; the price is current.
Revenue Growth
4Y CAGR
2.1%
Revenue moved from $21.90B in 2016 to $17.26B in 2025, a -2.6% compound annual growth rate. The most recent year was roughly flat (4.4%) year over year. Slower, mature growth is common for established businesses.
Profitability
Gross Margin
51.8%
Operating Margin
12.5%
Net Margin
8.2%
ROE
20.7%
Teva Pharmaceutical Industries Ltd keeps about 9.0% of each sales dollar as net profit, with a 51.8% gross margin and 12.5% operating margin. Return on equity is 20.7% and return on invested capital about 5.0%. Margins are moderate — typical of a competitive but profitable business.
Debt Analysis
Total Debt
$28.83B
Net Debt
$25.17B
Net Debt / EBITDA
11.67x
Debt / Equity
2.12x
Leverage: debt-to-equity is 2.1x, and operating profit covers interest about 2.4x, with a current ratio of 0.9x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $28.83B of total debt against $3.65B of cash.
Cash Flow Analysis
Operating CF
$1.65B
Free Cash Flow
$1.15B
FCF Margin
6.7%
In the latest year Teva Pharmaceutical Industries Ltd produced about $1.65B of operating cash flow and $1.15B of free cash flow after capital spending. That is a free-cash-flow yield of about -10.5% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Dividend Safety
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
What to look for in a dividend stockThe dividend is being paid, but coverage or consistency is thinner than an income investor should rely on without a closer look.
Per share (latest FY)
$0.85
Total paid (latest FY)
$12.00M
History on record
3 years
dividend uses 1% of free cash flow
1% of net income paid out
no current raise streak
payout was cut at least once in the last 3 years
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
Valuation Analysis
P/E
25.77x
P/S
2.34x
P/B
4.87x
EV / EBITDA
18.4x
TEVA trades at 25.8x trailing earnings, 2.3x sales, and 4.9x book value. Reverse-engineering today's price implies the market expects roughly 5.3% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
DCF Fair Value (Educational)
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
How this DCF estimate is calculatedDCF fair value / share
$17.31
Current price
$41.16
Starting FCF (latest 10-K)
$1.15B
Growth, years 1–5
4.4%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Metrics vs. Sector Range
Where TEVA sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How TEVA stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
Among the 83 rated Health Care companies we cover, TEVA ranks #72 by our overall rating. It trades at roughly in line versus the sector on earnings (25.8x P/E vs. 26.1x median) with a higher return on equity (20.7% vs. 14.1%) and slower revenue growth (4.4% vs. 7.6%).
P/E vs sector
25.8x
median 26.1x
ROE vs sector
20.7%
median 14.1%
Growth vs sector
4.4%
median 7.6%
Sector rank
#72
of 83 rated
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
5-Year Projection Model
Project revenue → earnings → price. Edit the assumptions to build your own case.
What drives this projection, and its limits2030 scenario price range (Base Case)
$33.57 – $54.55
vs. $41.16 today · implied CAGR -4% – 6%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $17.95B | $18.67B | $19.41B | $20.19B | $21.00B |
| Net income | $1.44B | $1.49B | $1.55B | $1.62B | $1.68B |
| EPS | $1.79 | $1.87 | $1.94 | $2.02 | $2.10 |
| Share price (low) | $28.69 | $29.84 | $31.04 | $32.28 | $33.57 |
| Share price (high) | $46.63 | $48.49 | $50.43 | $52.45 | $54.55 |
| CAGR (low–high) | -30% / 13% | -15% / 9% | -9% / 7% | -6% / 6% | -4% / 6% |
Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions.
Bull Case
The case for TEVA:
- Strong return on equity (20.7%) shows capital is put to work well.
Bear Case
The case against TEVA:
- Elevated leverage (debt/equity 2.1x) adds financial risk.
- Interest coverage is thin (2.4x), so debt costs bite.
- Limited free cash flow at today's price.
- Our model's overall read is Weak (33/100).
Key Risks
Balance-sheet risk — debt/equity of 2.1x magnifies the impact of higher rates or weaker earnings.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Investment Thesis
On balance, the fundamentals screen weakly: Teva Pharmaceutical Industries Ltd is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 25.8x earnings, which our model scores Weak (33/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 7 Wall Street analysts covering TEVA recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
TEVA's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
TEVA — frequently asked questions
Is TEVA a good stock to buy?
We don't give buy or sell advice. Our model rates Teva Pharmaceutical Industries Ltd Weak (33/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is TEVA's rating on The Stocks School?
Teva Pharmaceutical Industries Ltd currently scores 33/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does TEVA's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Teva Pharmaceutical Industries Ltd's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for TEVA calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this TEVA analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell TEVA. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.